LAUNCHING TODAY | The Israeli Cannabis Report

About

Prohibition Partners proudly announces the release of The Israeli Cannabis Report, a comprehensive analysis of Israel’s journey as a pioneer in the medical cannabis sector. This report offers an in-depth exploration of the country’s advancements from its early research phases in the 1960s to its current position as a global leader in the medical cannabis landscape.

Introduction

Israel’s evolution in the medical cannabis industry is a unique narrative characterized by innovative scientific discoveries, progressive regulatory evolutions, and a dynamic market environment. Over several decades, Israel has successfully navigated numerous legislative, medical, and commercial challenges, emerging as a beacon of what regulated cannabis industries can achieve globally. Central to this success is Israel’s commitment to rigorous scientific research, adaptable regulatory frameworks, and a steadfast focus on patient welfare. These elements have significantly propelled the advancement and international perception of cannabis as a legitimate medical solution.

Regulatory Reform

The Israeli cannabis industry is on the cusp of transformative change with a series of regulatory reforms scheduled for implementation this year. These reforms are expected to overhaul the medical cannabis landscape, enhancing patient access and regulatory compliance. The report delves into the specifics of these reforms, examining their potential to streamline processes, lessen economic burdens on patients, and bolster public trust and acceptance of medical cannabis.

Patient Access

By December 2023, Israel boasted the highest per capita rate of medical cannabis patients worldwide, a testament to its robust patient access initiatives. The forthcoming reforms in 2024 are set to further transform patient access, potentially doubling the number of patients. These changes are aligned with global trends and regulatory shifts, promising to make medical cannabis more accessible and affordable for Israeli patients.

Competitor & Product Landscape

The report provides a detailed overview of Israel’s cannabis ecosystem, highlighting key players and the array of medical cannabis products available. It maps out the competitive landscape, showcasing the innovation and diversity within the market. This section also examines the strategic positioning of Israeli companies, particularly their compliance with EU-GMP standards, which is crucial for penetrating the European market, including the burgeoning German sector.

Future Outlook

Looking ahead, Israel’s Ministry of Health is at the forefront of a transformative journey to overhaul the country’s mandatory healthcare system. With a focus on innovation, Israel’s cannabis industry continues to thrive, driven by cutting-edge research and development. Government support and private investment are propelling advancements in novel products and therapeutic applications, such as advanced inhaler technologies and nanotech-based formulations. These innovations are set to usher in a new era of cannabis consumption and treatment methodologies.

Israeli Product & Market Sizing Data

Alongside the report, a comprehensive dataset is available for purchase on our website. This dataset encompasses information on nearly 1000 products, including 638 flower products, 192 oil products, and 15 pre-roll products. The data includes pricing, characterization, marketer details, THC and CBD percentages, series, brand, and manufacturing country. Additionally, the dataset offers market sizing and patient population forecasts from 2023 to 2027, providing valuable insights into the future trajectory of the Israeli cannabis market.

Conclusion

The Israeli Cannabis Report is now available for free download via our website. This detailed analysis underscores Israel’s role as a global leader in the medical cannabis sector. With over 137,940 licensed patients by 2023 and a significant increase in exports and product diversity, Israel exemplifies the power of integrating research with patient needs to shape policy and market dynamics. As the industry continues to evolve, Israel’s analytical approach to policy-making, commitment to research, and adaptive regulatory framework ensure its continued leadership and influence in global cannabis research and commerce.

Recent Posts

• October 16, 2024 – Medical Cannabis Sales in Germany Expected to Reach 420 Million in 2024
• January 31, 2024 – New Reforms Set to Send Israeli Medical Cannabis Patient Numbers Soaring
• January 23, 2024 – Launching Today | Oceania Regulatory Report
• December 14, 2023 – Launching Today | The Global Cannabis Report: 4th Edition